One proposed cocktail, baloxavir marboxil, natamycin and RU85053, targets three viral proteins respectively, 3CL Main protease, papain-like protease and RdRp.
The research group is working on developing new drug candidates against SARS-CoV-2 by exploring DrugBank database compounds as an inhibitor of SARS-CoV-2 main protease, a key enzyme required for SARS-CoV-2 assembly and multiplication.